生長激素缺乏症 (GHD) - 到2024年的流行病學預測
EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026
|出版日期||內容資訊||英文 36 Pages
|生長激素缺乏症 (GHD) - 到2024年的流行病學預測 EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026|
|出版日期: 2017年06月01日||內容資訊: 英文 36 Pages||
生長激素缺乏症 (GHD) ，是特徵為生長激素低或分泌不足的內分泌障礙。在全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)生長激素缺乏症 (GHD) 和確診的發病數量，預計從2014年的97,985件，到2024年達100,494件，增加0.26％。
本報告提供全球主要7個國家的生長激素缺乏症 (GHD) 調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。
GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development.
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26%. Our epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan.
In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13%, of all cases of GHD in the 7MM. Our epidemiologists maintained a consistent forecast methodology across all the 7MM, which allows for comparison between each of the seven markets. Due to the limited availability of market-specific epidemiological studies available, further research is needed to better understand inter-market variations of the epidemiological parameters.
The report "EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026" provides an overview of the risk factors, comorbidities, and global trends for GHD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex from 2016 to 2026. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD (COGHD) and adult onset GHD (AOGHD).
The GHD EpiCast report will allow you to -